SEATTLE, Oct. 25, 2016 /PRNewswire/ -- PhaseRx, Inc. (NASDAQ: PZRX), a biopharmaceutical company developing mRNA products to correct life-threatening inherited liver diseases in children, today announced that the company will present data evaluating its mRNA Hybrid Technology platform at the 4th International mRNA Health Conference taking place November 1-2, 2016 in Boston. The poster, titled, 'Targeted mRNA delivery to the liver for Intracellular Enyzme Replacement Therapy (i-ERT)' will be presented by Pierrot Harvie, Ph.D., Associate Director of Formulations at PhaseRx. The poster will be in session 6 at the Westin Boston Waterfront, 425 Summer Street, Boston, MA.
PhaseRx is a biopharmaceutical company developing a portfolio of mRNA products to correct life-threatening inherited liver diseases in children. PhaseRx's initial product development focus is on urea cycle disorders, a group of rare genetic diseases that generally present before the age of 12 and are characterized by the body's inability to remove ammonia from the blood. The company's i-ERT approach is enabled by its proprietary Hybrid mRNA Technology™ platform and is applicable to a significant number of inherited liver diseases. PhaseRx is headquartered in Seattle. For more information, please visit www.phaserx.com.
Director of Investor Relations
Senior Vice President
Robert H. Uhl
Westwicke Partners, LLC
For more information:
Last updated on: 26/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.